| ORIGINAL ARTICLE |
|
| Year : 2020 | Volume
: 4
| Issue : 4 | Page : 318-322 |
|
|
Synthesis, characterization, and In vitro antibacterial activity and molecular docking studies of N4, N4'-dibutyl-3,3'-dinitro-[1,1'-Biphenyl]-4,4'-diamine
K Muddukrishnaiah1, V Vijayakumar2, B Samuel Thavamani3, VP Shilpa3, N Radhakrishnan2, Heba S Abbas4
1 Department of Pharmaceutical Technology, Anna University, BIT Campus, Tiruchirappalli, India
2 Department of Chemistry, Anna University, CEG Campus, Chennai, Tamil Nadu, India
3 Department of Pharmacy, Sanjo College of Pharmaceutical Studies, Palakkad, Kerala, India
4 Department of Microbiology, National Organization for Drug Control and Research, Giza, Egypt
Correspondence Address:
Mr. K Muddukrishnaiah
Department of Pharmaceutical Technology, Anna University, BIT Campus, Tiruchirappallu - 620 024, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bbrj.bbrj_52_20
|
|
|
Background: Resistant growth is recognized as a significant public health hazard to human health worldwide among the most critical bacterial diseases. The evolving multidrug-resistant species are now commonly found in community settings, not just in the hospital area, which means that antibiotic bacteria reservoirs are beyond the hospital. Aim: In this study, we synthesized novel N4, N4'-dibutyl-3,3'-dinitro-[1,1'-biphenyl]-4,4'-diamine from 3,3'-dinitro-[1,1'-biphenyl]-4,4'-diamine and evaluation of its antimicrobial activity against clinical bacteria. Methods: Single-step synthesis of novel N4, N4'-dibutyl-3,3'-dinitro-[1,1'-biphenyl]-4,4'-diamine from 3,3'-dinitro-[1,1'-biphenyl]-4,4'-diamine and well characterized using spectroscopic methods, namely FT-IR, NMR, mass spectrometry, and CHNS. Besides, prepared compound molecular docking investigations, molecular physicochemical, absorption, distribution, metabolism, and excretion (ADME) analysis were also carried out. Results and Discussion: Novel Synthesized N4, N4'-dibutyl-3,3'-diaminobenzidine (DAB) was conducted for antibacterial activity against clinical Klebsiella spp. and Staphylococcus aureus and Pseudomonas spp. by the disc-diffusion method and followed by serial dilution method. N4, N4'-dibutyl-3,3'-DAB showed bacteriostatic action of 500 μg/ml, 1000 μg/ml for Klebsiella spp. and Staphylococcus aureus. The molecular physicochemical investigation exhibited that 1 violation and ADME analysis presented a low gastro intestinal effect. Docking investigations disclosed the capability of synthesized molecule potential to dock with beta-lactamase protein through patch dock methodology. Conclusion: N4, N4'-dibutyl-3,3'-DAB is the novel compound that was found to be attractive for the “drug hunters” as a potential agent for the management of infectious diseases against the human pathogens Klebsiella spp. and Staphylococcus aureus.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
| Article Access Statistics | | | Viewed | 614 | | | Printed | 24 | | | Emailed | 0 | | | PDF Downloaded | 80 | | | Comments | [Add] | | |
|
|
